Clovis Oncology Stock Price, News & Analysis (NASDAQ:CLVS)

$63.21 -3.67 (-5.49 %)
(As of 11/17/2017 02:18 PM ET)
Previous Close$63.21
Today's Range$63.15 - $67.09
52-Week Range$33.23 - $99.45
Volume1.44 million shs
Average Volume1.23 million shs
Market Capitalization$3.1 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.54

About Clovis Oncology (NASDAQ:CLVS)

Clovis Oncology logoClovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3. Rociletinib is an oral mutant-selective inhibitor of epidermal growth factor receptor (EGFR).


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Sector: Bio Therapeutic Drugs
  • Symbol: NASDAQ:CLVS
  • CUSIP: 18946410
  • Web: www.clovisoncology.com
Debt:
  • Debt-to-Equity Ratio: 0.94%
  • Current Ratio: 3.19%
  • Quick Ratio: 3.16%
Sales & Book Value:
  • Annual Sales: $80,000.00
  • Price / Sales: 38,724.03
  • Book Value: $6.10 per share
  • Price / Book: 10.36
Profitability:
  • Trailing EPS: ($8.28)
  • Net Income: ($349,130,000.00)
  • Net Margins: -947.47%
  • Return on Equity: -122.06%
  • Return on Assets: -38.84%
Misc:
  • Employees: 278
  • Outstanding Shares: 49,010,000
 

Frequently Asked Questions for Clovis Oncology (NASDAQ:CLVS)

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

How were Clovis Oncology's earnings last quarter?

Clovis Oncology, Inc. (NASDAQ:CLVS) released its earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($1.24) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.18) by $0.06. The biopharmaceutical company had revenue of $16.81 million for the quarter, compared to analyst estimates of $21.12 million. Clovis Oncology had a negative net margin of 947.47% and a negative return on equity of 122.06%. During the same quarter in the previous year, the firm earned ($1.70) EPS. View Clovis Oncology's Earnings History.

Where is Clovis Oncology's stock going? Where will Clovis Oncology's stock price be in 2017?

18 brokers have issued 12 month price targets for Clovis Oncology's shares. Their predictions range from $38.00 to $125.00. On average, they expect Clovis Oncology's stock price to reach $85.47 in the next year. View Analyst Ratings for Clovis Oncology.

What are Wall Street analysts saying about Clovis Oncology stock?

Here are some recent quotes from research analysts about Clovis Oncology stock:

  • 1. According to Zacks Investment Research, "Clovis’ Rubraca registered impressive sales in the second quarter. The FDA’s accelerated approval to ovarian cancer treatment, Rubraca in Dec 2016 was a huge boost for  the company. Rubraca has bright prospects, given the tremendous demand for PARP inhibitors. Clovis is focused on achieving continued approval for the drug. Rubraca is also under review in the EU for a comparable indication. Several studies on Rubraca, targeting different types of ovarian cancer patients, are currently underway. Promising progression-free survival and safety results from the ARIEL3 maintenance study in Jun 2017 are positives. However, with just one approved product in the portfolio, Clovis is heavily dependent on Rubraca for growth, which concerns us. Clovis’ shares have outperformed the industry so far this year. Loss Estimates have narrowed ahead of the Q3 earnings results. The company has a mixed record of earnings surprises in recent quarters." (10/17/2017)
  • 2. Cann analysts commented, "In a presentation on Saturday at the 2017 European Society for Medical Oncology (ESMO) Congress, Clovis Oncology released additional details from the results of the phase III ARIEL3 study of Rucraca. In addition to PFS results, Clovis presented response rate data from an exploratory analysis of investigator-assessed ORR for patients with measurable disease at baseline. These response rate data are consistent with the previously released PFS data." (9/11/2017)
  • 3. The Goldman Sachs Group, Inc. analysts commented, "AZN (covered by Keyur Parekh) presented data from a Ph3 SOLO-2 maintenance ovarian cancer trial of Lynparza (PARP inhibitor) on March 14 at the SGO conference, which we believe has implications for CLVS (lead marketed drug Rubraca is also a PARP). CLVS, AZN and TSRO (not covered) all have PARP inhibitors that they are evaluating for use in the maintenance treatment of ovarian cancer." (3/15/2017)
  • 4. Stifel Nicolaus analysts commented, "This price assumes about a 40% market share for rucaparib throughout addressable ovarian cancer (OC). However, in deriving this target, we include sales in the maintenance setting for ovarian cancer with a weighting of 75% (some risk remains to ARIEL3) and note that full weighing of this unapproved usage would suggest a fair value of about $104. Furthermore, inclusion of sales in mCRPC, which we consider highly promising but where large trials are just starting, suggests a fair value for Clovis shares of about $182. We consider most of the ongoing trials for rucaparib to be relatively low risk, but with several other players also competing for each indication we believe a takeout price of about 50% of our best case scenario makes sense." (1/23/2017)

Who are some of Clovis Oncology's key competitors?

Who are Clovis Oncology's key executives?

Clovis Oncology's management team includes the folowing people:

  • M. James E. Barrett Ph.D., Independent Chairman of the Board (Age 74)
  • Patrick J. Mahaffy, President, Chief Executive Officer, Director (Age 54)
  • Daniel W. Muehl, Senior Vice President of Finance, Principal Accounting Officer and Principal Financial Officer (Age 54)
  • Gillian C. Ivers-Read, Executive Vice President - Technical Operations, Chief Regulatory Officer (Age 63)
  • Lindsey Rolfe BSc, MB ChB, MRCP, F, Executive Vice President - Clinical and Pre-Clinical Development and Pharmacovigilance and Chief Medical Officer (Age 49)
  • C. Dale Hooks, Senior Vice President, Chief Commercial Officer (Age 50)
  • Brian G. Atwood, Independent Director (Age 64)
  • James C. Blair Ph.D., Independent Director (Age 77)
  • Keith T. Flaherty M.D., Independent Director (Age 46)
  • Ginger L. Graham, Independent Director (Age 61)

Who owns Clovis Oncology stock?

Clovis Oncology's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Orbimed Advisors LLC (4.87%), Jennison Associates LLC (1.22%), Macquarie Group Ltd. (1.08%), Westfield Capital Management Co. LP (0.94%), Pictet Asset Management Ltd. (0.75%) and Emerald Advisers Inc. PA (0.68%). Company insiders that own Clovis Oncology stock include Gillian C Ivers-Read and James C Blair. View Institutional Ownership Trends for Clovis Oncology.

Who sold Clovis Oncology stock? Who is selling Clovis Oncology stock?

Clovis Oncology's stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Wells Fargo & Company MN, Janus Henderson Group PLC, Crawford Lake Capital Management LLC, Canada Pension Plan Investment Board, Chicago Equity Partners LLC, Asymmetry Capital Management L.P. and TD Asset Management Inc.. Company insiders that have sold Clovis Oncology company stock in the last year include Gillian C Ivers-Read and James C Blair. View Insider Buying and Selling for Clovis Oncology.

Who bought Clovis Oncology stock? Who is buying Clovis Oncology stock?

Clovis Oncology's stock was bought by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Sectoral Asset Management Inc, Macquarie Group Ltd., Sector Gamma AS, Westfield Capital Management Co. LP, Frontier Capital Management Co. LLC, Columbus Circle Investors and Artal Group S.A.. View Insider Buying and Selling for Clovis Oncology.

How do I buy Clovis Oncology stock?

Shares of Clovis Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Clovis Oncology's stock price today?

One share of Clovis Oncology stock can currently be purchased for approximately $63.21.

How big of a company is Clovis Oncology?

Clovis Oncology has a market capitalization of $3.1 billion and generates $80,000.00 in revenue each year. The biopharmaceutical company earns ($349,130,000.00) in net income (profit) each year or ($8.28) on an earnings per share basis. Clovis Oncology employs 278 workers across the globe.

How can I contact Clovis Oncology?

Clovis Oncology's mailing address is 5500 Flatiron Pkwy Unit 100, BOULDER, CO 80301-2834, United States. The biopharmaceutical company can be reached via phone at +1-303-6255000 or via email at [email protected]


MarketBeat Community Rating for Clovis Oncology (NASDAQ CLVS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  346 (Vote Outperform)
Underperform Votes:  275 (Vote Underperform)
Total Votes:  621
MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Clovis Oncology (NASDAQ:CLVS)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 7 Hold Ratings, 11 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.61)
Consensus Price Target: $85.47 (35.21% upside)

Consensus Price Target History for Clovis Oncology (NASDAQ:CLVS)

Price Target History for Clovis Oncology (NASDAQ:CLVS)

Analysts' Ratings History for Clovis Oncology (NASDAQ:CLVS)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/15/2017Leerink SwannReiterated RatingOutperform$107.00 -> $90.00N/AView Rating Details
11/3/2017Stifel NicolausReiterated RatingBuy$125.00N/AView Rating Details
11/2/2017Morgan StanleyLower Price TargetOverweight$89.00 -> $86.00N/AView Rating Details
10/23/2017Barclays PLCInitiated CoverageOverweight -> Overweight$105.00N/AView Rating Details
10/10/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldN/AView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageSector Perform$81.00LowView Rating Details
9/11/2017CannReiterated RatingHoldLowView Rating Details
8/18/2017J P Morgan Chase & CoReiterated RatingBuyMediumView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$73.00HighView Rating Details
8/3/2017Bank of America CorporationReiterated RatingBuyLowView Rating Details
7/18/2017Credit Suisse GroupSet Price TargetBuy$107.00LowView Rating Details
7/7/2017GabelliInitiated CoverageBuy$125.00HighView Rating Details
6/22/2017SunTrust Banks, Inc.Reiterated RatingBuyLowView Rating Details
6/20/2017The Goldman Sachs Group, Inc.Reiterated RatingNeutral$67.00 -> $90.00HighView Rating Details
6/20/2017Janney Montgomery ScottUpgradeNeutral -> BuyMediumView Rating Details
6/19/2017Chardan CapitalUpgradeSell -> Neutral$36.00 -> $50.00HighView Rating Details
3/28/2017Piper Jaffray CompaniesSet Price TargetBuy$77.00LowView Rating Details
12/21/2016WallachBeth CapitalBoost Price TargetHold$22.00 -> $49.00N/AView Rating Details
8/24/2016MizuhoBoost Price TargetNeutral$15.00 -> $23.00N/AView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for Clovis Oncology (NASDAQ:CLVS)

Earnings by Quarter for Clovis Oncology (NASDAQ:CLVS)

Earnings History by Quarter for Clovis Oncology (NASDAQ CLVS)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017Q3 2017($1.18)($1.24)$21.12 million$16.81 millionViewN/AView Earnings Details
8/2/2017Q2 2017($1.27)($1.29)$13.07 million$14.62 millionViewListenView Earnings Details
5/3/2017Q1 2017($1.43)($1.33)$6.04 million$7.05 millionViewListenView Earnings Details
2/22/2017Q416($1.65)($1.83)$0.08 millionViewListenView Earnings Details
11/3/2016Q316($1.95)($1.70)ViewListenView Earnings Details
8/8/2016Q216($2.13)($2.07)ViewListenView Earnings Details
5/5/2016Q116($2.39)($2.17)ViewListenView Earnings Details
2/25/2016Q415($2.39)($2.23)ViewListenView Earnings Details
11/5/2015Q315($2.07)($2.62)ViewListenView Earnings Details
8/6/2015Q215($2.11)($2.10)$1.17 millionViewListenView Earnings Details
5/6/2015Q115($1.78)($1.86)$13.60 millionViewListenView Earnings Details
2/25/2015Q414($1.41)($1.62)ViewListenView Earnings Details
11/6/2014Q314($1.03)($1.17)ViewListenView Earnings Details
8/7/2014Q214($0.93)($1.03)$13.60 millionViewListenView Earnings Details
5/8/2014Q114($0.85)($0.91)$13.60 millionViewListenView Earnings Details
2/27/2014Q4($0.78)($0.92)ViewListenView Earnings Details
10/31/2013Q313($0.68)($0.68)ViewListenView Earnings Details
8/1/2013Q2 2013($0.65)($0.72)ViewListenView Earnings Details
5/7/2013Q1 2013($0.60)($0.60)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Clovis Oncology (NASDAQ:CLVS)
2017 EPS Consensus Estimate: ($5.16)
2018 EPS Consensus Estimate: ($2.79)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.53)($1.53)($1.53)
Q2 20173($1.30)($1.18)($1.23)
Q3 20173($1.24)($1.10)($1.15)
Q4 20173($1.31)($1.23)($1.26)
Q1 20182($1.38)($1.16)($1.27)
Q2 20182($1.01)($0.68)($0.85)
Q3 20182($0.64)($0.46)($0.55)
Q4 20182($0.17)($0.08)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Clovis Oncology (NASDAQ:CLVS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Clovis Oncology (NASDAQ CLVS)

Insider Ownership Percentage: 12.50%
Institutional Ownership Percentage: 98.53%
Insider Trades by Quarter for Clovis Oncology (NASDAQ:CLVS)
Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)

Insider Trades by Quarter for Clovis Oncology (NASDAQ CLVS)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/15/2017Gillian C Ivers-ReadInsiderSell3,000$63.70$191,100.00View SEC Filing  
10/16/2017Gillian C Ivers-ReadInsiderSell3,000$84.54$253,620.00View SEC Filing  
9/15/2017Gillian C Ivers-ReadInsiderSell3,000$69.50$208,500.00View SEC Filing  
8/15/2017Gillian C Ivers-ReadInsiderSell3,000$70.05$210,150.00View SEC Filing  
8/4/2017James C BlairDirectorSell18,450$78.61$1,450,354.50View SEC Filing  
7/17/2017Gillian C Ivers-ReadInsiderSell3,000$91.56$274,680.00View SEC Filing  
6/15/2017Gillian C Ivers-ReadInsiderSell3,000$61.82$185,460.00View SEC Filing  
5/15/2017Gillian C Ivers-ReadInsiderSell3,000$47.39$142,170.00View SEC Filing  
4/17/2017Gillian C Ivers-ReadInsiderSell3,000$56.02$168,060.00View SEC Filing  
3/15/2017Gillian C Ivers-ReadInsiderSell3,000$66.99$200,970.00View SEC Filing  
11/2/2015Erle T. MastCFOSell3,000$105.56$316,680.00View SEC Filing  
10/28/2015Lindsey RolfeinsiderSell4,000$98.02$392,080.00View SEC Filing  
10/15/2015Gillian C Ivers-ReadInsiderSell3,000$91.91$275,730.00View SEC Filing  
10/5/2015Lindsey RolfeinsiderSell4,000$93.04$372,160.00View SEC Filing  
10/1/2015Erle T. MastCFOSell3,000$90.22$270,660.00View SEC Filing  
9/18/2015Gillian C Ivers-ReadInsiderSell3,000$112.56$337,680.00View SEC Filing  
9/1/2015Erle T. MastCFOSell3,000$79.51$238,530.00View SEC Filing  
7/1/2015Erle T MastCFOSell3,000$85.70$257,100.00View SEC Filing  
6/1/2015Erle T MastCFOSell3,000$88.78$266,340.00View SEC Filing  
5/15/2015M James BarrettDirectorSell2,424$92.43$224,050.32View SEC Filing  
4/1/2015Erle T MastCFOSell3,000$71.25$213,750.00View SEC Filing  
3/9/2015Erle T MastCFOSell9,000$78.84$709,560.00View SEC Filing  
3/5/2015James C BlairDirectorSell8,528$77.70$662,625.60View SEC Filing  
1/16/2015Steven L HoerterInsiderSell10,000$67.00$670,000.00View SEC Filing  
12/11/2013Erle MastCFOSell50,000$52.78$2,639,000.00View SEC Filing  
12/5/2013Thorlef SpickschenDirectorSell9,000$56.10$504,900.00View SEC Filing  
6/5/2013Andrew R AllenInsiderSell22,594$68.54$1,548,592.76View SEC Filing  
6/4/2013M James BarrettDirectorSell2,483$70.80$175,796.40View SEC Filing  
6/4/2013Parters Vii L P DomainMajor ShareholderSell159,192$64.58$10,280,619.36View SEC Filing  
6/4/2013Steven L HoerterInsiderSell10,000$73.06$730,600.00View SEC Filing  
3/6/2013Parters Vii L P DomainMajor ShareholderSell250,000$24.59$6,147,500.00View SEC Filing  
8/16/2012Edward J MckinleyDirectorBuy9,701$15.50$150,365.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Clovis Oncology (NASDAQ:CLVS)

Latest Headlines for Clovis Oncology (NASDAQ CLVS)

Source:
DateHeadline
Leerink Swann Comments on Clovis Oncology, Inc.s FY2018 Earnings (CLVS)Leerink Swann Comments on Clovis Oncology, Inc.'s FY2018 Earnings (CLVS)
www.americanbankingnews.com - November 18 at 9:38 AM
Oversold Conditions For Clovis Oncology (CLVS)Oversold Conditions For Clovis Oncology (CLVS)
www.nasdaq.com - November 18 at 8:40 AM
Clovis Oncology, Inc. (CLVS) Insider Gillian C. Ivers-Read Sells 3,000 SharesClovis Oncology, Inc. (CLVS) Insider Gillian C. Ivers-Read Sells 3,000 Shares
www.americanbankingnews.com - November 16 at 8:37 PM
Notable Friday Option Activity: ICPT, GILD, CLVSNotable Friday Option Activity: ICPT, GILD, CLVS
www.nasdaq.com - November 10 at 5:04 PM
Clovis Oncology to Present at the Stifel 2017 Healthcare Conference - Business Wire (press release)Clovis Oncology to Present at the Stifel 2017 Healthcare Conference - Business Wire (press release)
www.businesswire.com - November 10 at 9:49 AM
Clovis Oncology, Inc. (CLVS) Receives Average Recommendation of "Buy" from AnalystsClovis Oncology, Inc. (CLVS) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 9 at 10:16 AM
Clovis Oncology, Inc. breached its 50 day moving average in a Bullish Manner : CLVS-US : November 8, 2017Clovis Oncology, Inc. breached its 50 day moving average in a Bullish Manner : CLVS-US : November 8, 2017
finance.yahoo.com - November 8 at 9:17 PM
Clovis Oncology to Present at the Stifel 2017 Healthcare ConferenceClovis Oncology to Present at the Stifel 2017 Healthcare Conference
finance.yahoo.com - November 8 at 9:17 PM
Q4 2017 Earnings Forecast for Clovis Oncology, Inc. Issued By Oppenheimer Holdings (CLVS)Q4 2017 Earnings Forecast for Clovis Oncology, Inc. Issued By Oppenheimer Holdings (CLVS)
www.americanbankingnews.com - November 8 at 4:32 PM
Clovis Oncology, Inc. (CLVS) to Post Q4 2017 Earnings of ($1.23) Per Share, Oppenheimer Holdings ForecastsClovis Oncology, Inc. (CLVS) to Post Q4 2017 Earnings of ($1.23) Per Share, Oppenheimer Holdings Forecasts
www.americanbankingnews.com - November 6 at 9:38 AM
Gabelli Brokers Boost Earnings Estimates for Clovis Oncology, Inc. (CLVS)Gabelli Brokers Boost Earnings Estimates for Clovis Oncology, Inc. (CLVS)
www.americanbankingnews.com - November 6 at 6:36 AM
FY2017 EPS Estimates for Clovis Oncology, Inc. Lowered by Analyst (CLVS)FY2017 EPS Estimates for Clovis Oncology, Inc. Lowered by Analyst (CLVS)
www.americanbankingnews.com - November 6 at 6:36 AM
SunTrust Banks Weighs in on Clovis Oncology, Inc.s FY2017 Earnings (CLVS)SunTrust Banks Weighs in on Clovis Oncology, Inc.'s FY2017 Earnings (CLVS)
www.americanbankingnews.com - November 6 at 6:36 AM
Clovis Oncologys (CLVS) Buy Rating Reiterated at Stifel NicolausClovis Oncology's (CLVS) Buy Rating Reiterated at Stifel Nicolaus
www.americanbankingnews.com - November 4 at 6:42 PM
Notable Thursday Option Activity: CLVS, GOGO, ENDPNotable Thursday Option Activity: CLVS, GOGO, ENDP
www.thestreet.com - November 2 at 6:07 PM
Edited Transcript of CLVS earnings conference call or presentation 1-Nov-17 8:30pm GMTEdited Transcript of CLVS earnings conference call or presentation 1-Nov-17 8:30pm GMT
finance.yahoo.com - November 2 at 6:06 PM
Clovis reports 3Q lossClovis reports 3Q loss
finance.yahoo.com - November 1 at 11:08 PM
Clovis Oncology Announces Third Quarter 2017 Operating Results - Business Wire (press release)Clovis Oncology Announces Third Quarter 2017 Operating Results - Business Wire (press release)
www.businesswire.com - November 1 at 6:05 PM
Clovis Oncology, Inc. to Host Earnings CallClovis Oncology, Inc. to Host Earnings Call
finance.yahoo.com - November 1 at 6:05 PM
Clovis Oncology Announces Third Quarter 2017 Operating ResultsClovis Oncology Announces Third Quarter 2017 Operating Results
finance.yahoo.com - November 1 at 6:05 PM
Neurocrine, Exelixis, Juno Stocks Rocket After Crushing ViewsNeurocrine, Exelixis, Juno Stocks Rocket After Crushing Views
finance.yahoo.com - November 1 at 6:05 PM
Clovis Oncology, Inc. (CLVS) Issues Quarterly  Earnings ResultsClovis Oncology, Inc. (CLVS) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 1 at 5:46 PM
Is a Turnaround in Store for Teva (TEVA) in Q3 Earnings?Is a Turnaround in Store for Teva (TEVA) in Q3 Earnings?
www.nasdaq.com - October 30 at 4:02 PM
MGNX Soars On INCY Deal, CDTX Strides Ahead, NUVA Entices, ACHC In Poor HealthMGNX Soars On INCY Deal, CDTX Strides Ahead, NUVA Entices, ACHC In Poor Health
www.nasdaq.com - October 25 at 11:52 PM
Clovis Oncology, Inc. – Value Analysis (NASDAQ:CLVS) : October 25, 2017Clovis Oncology, Inc. – Value Analysis (NASDAQ:CLVS) : October 25, 2017
finance.yahoo.com - October 25 at 6:49 PM
Clovis Oncology, Inc. (CLVS) Set to Announce Earnings on WednesdayClovis Oncology, Inc. (CLVS) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - October 25 at 3:48 AM
Clovis Oncology, Inc. breached its 50 day moving average in a Bearish Manner : CLVS-US : October 24, 2017Clovis Oncology, Inc. breached its 50 day moving average in a Bearish Manner : CLVS-US : October 24, 2017
finance.yahoo.com - October 24 at 7:40 PM
Clovis Oncology to Announce Third Quarter 2017 Financial Results and Host Webcast Conference Call on November 1Clovis Oncology to Announce Third Quarter 2017 Financial Results and Host Webcast Conference Call on November 1
finance.yahoo.com - October 23 at 5:53 PM
Clovis Oncology, Inc. (CLVS) Expected to Post Quarterly Sales of $20.46 MillionClovis Oncology, Inc. (CLVS) Expected to Post Quarterly Sales of $20.46 Million
www.americanbankingnews.com - October 21 at 8:14 AM
Zacks: Analysts Anticipate Clovis Oncology, Inc. (CLVS) to Post -$1.16 EPSZacks: Analysts Anticipate Clovis Oncology, Inc. (CLVS) to Post -$1.16 EPS
www.americanbankingnews.com - October 19 at 8:19 AM
Insider Selling: Clovis Oncology, Inc. (CLVS) Insider Sells 3,000 Shares of StockInsider Selling: Clovis Oncology, Inc. (CLVS) Insider Sells 3,000 Shares of Stock
www.americanbankingnews.com - October 17 at 10:20 PM
Head-To-Head Analysis: Clovis Oncology (CLVS) and Its RivalsHead-To-Head Analysis: Clovis Oncology (CLVS) and Its Rivals
www.americanbankingnews.com - October 16 at 12:08 AM
Clovis Oncology, Inc. (CLVS) Receives Average Rating of "Buy" from AnalystsClovis Oncology, Inc. (CLVS) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - October 15 at 10:44 AM
Clovis (CLVS) Submits sNDA for Ovarian Cancer Drug RubracaClovis (CLVS) Submits sNDA for Ovarian Cancer Drug Rubraca
finance.yahoo.com - October 10 at 6:28 PM
Clovis Oncology Submits Supplemental New Drug Application for Rucaparib as Maintenance Treatment for Patients with Platinum-Sensitive Recurrent Ovarian CancerClovis Oncology Submits Supplemental New Drug Application for Rucaparib as Maintenance Treatment for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
finance.yahoo.com - October 9 at 5:56 PM
Clovis Oncology Scores Relative Strength Rating UpgradeClovis Oncology Scores Relative Strength Rating Upgrade
finance.yahoo.com - October 2 at 5:36 PM
 Analysts Expect Clovis Oncology, Inc. (CLVS) Will Announce Earnings of -$1.17 Per Share Analysts Expect Clovis Oncology, Inc. (CLVS) Will Announce Earnings of -$1.17 Per Share
www.americanbankingnews.com - September 30 at 2:22 PM
Clovis: An Attractive M&A Candidate - Seeking AlphaClovis: An Attractive M&A Candidate - Seeking Alpha
seekingalpha.com - September 28 at 10:14 PM
Clovis Oncology, Inc. breached its 50 day moving average in a Bullish Manner : CLVS-US : September 25, 2017Clovis Oncology, Inc. breached its 50 day moving average in a Bullish Manner : CLVS-US : September 25, 2017
finance.yahoo.com - September 25 at 12:27 PM
Analyzing Clovis Oncology (CLVS) and CytomX Therapeutics (CTMX)Analyzing Clovis Oncology (CLVS) and CytomX Therapeutics (CTMX)
www.americanbankingnews.com - September 19 at 6:10 PM
Todays Research Reports on Stocks to Watch: Dimension Therapeutics and Clovis OncologyToday's Research Reports on Stocks to Watch: Dimension Therapeutics and Clovis Oncology
finance.yahoo.com - September 19 at 5:17 PM
Clovis Oncology (CLVS) in Focus: Stock Moves 10.5% HigherClovis Oncology (CLVS) in Focus: Stock Moves 10.5% Higher
finance.yahoo.com - September 19 at 5:17 PM
Clovis Oncology, Inc. (CLVS) Rating Reiterated by Leerink SwannClovis Oncology, Inc. (CLVS) Rating Reiterated by Leerink Swann
www.americanbankingnews.com - September 19 at 2:32 PM
Health Care Sector Update for 09/18/2017: CLVS,LLY,ITUS,AEMD - NasdaqHealth Care Sector Update for 09/18/2017: CLVS,LLY,ITUS,AEMD - Nasdaq
www.nasdaq.com - September 19 at 3:28 AM
Clovis Oncology Inc. (CLVS) Has Broken Out Of Todays RangeClovis Oncology Inc. (CLVS) Has Broken Out Of Today's Range
www.rttnews.com - September 18 at 5:20 PM
So Much PARP Inhibitor Deal Hype, So Little PayoffSo Much PARP Inhibitor Deal Hype, So Little Payoff
finance.yahoo.com - September 18 at 5:20 PM
Clovis Up 10% On Double Normal VolumeClovis Up 10% On Double Normal Volume
finance.yahoo.com - September 18 at 5:20 PM
Clovis Oncology Higher Off Unconfirmed Takeover ChatterClovis Oncology Higher Off Unconfirmed Takeover Chatter
feeds.benzinga.com - September 18 at 12:34 PM
Clovis Oncology, Inc. (CLVS) Now Covered by Royal Bank Of CanadaClovis Oncology, Inc. (CLVS) Now Covered by Royal Bank Of Canada
www.americanbankingnews.com - September 14 at 6:06 PM
Clovis Oncology (CLVS) ARIEL3 Study of Rucaparib Published in The Lancet - StreetInsider.comClovis Oncology (CLVS) ARIEL3 Study of Rucaparib Published in The Lancet - StreetInsider.com
www.streetinsider.com - September 13 at 11:32 PM

Social Media

Financials

Chart

Clovis Oncology (NASDAQ CLVS) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.